US Edition
Research to Watch: CAN-2409 Demonstrates Survival Benefit in Patients with Advanced NSCLC Unresponsive to ICIs - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Research to Watch: CAN-2409 Demonstrates Survival Benefit in Patients with Advanced NSCLC Unresponsive to ICIs - ILCN.org (ILCN/WCLC)
The final survival data from a phase IIa clinical trial revealed that the investigational treatment CAN-2409 may extend survival beyond standard-of-care docetaxel when combined with continued immune checkpoint inhibitor (ICI) treatment, according to a press release from the manufacturer Candel Therapeutics Inc.1 Key Findings According to the data, the median overall survival (mOS) among patients with advanced non-small cell lung cancer (NSCLC) w…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
